A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction
- First Posted Date
- 2016-06-27
- Last Posted Date
- 2017-09-07
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT02814097
- Locations
- 🇷🇸
Clinical Center Niš, Clinic for Cardiology, Niš, Serbia
🇷🇸Clinical Hospital Center "Dr Dragiša Mišović-Dedinje", Department of Cardiology, Belgrade, Serbia
🇷🇸Clinical Hospital Center "Bežanijska Kosa", Department of Cardiology, Belgrade, Serbia
Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study
- First Posted Date
- 2016-06-20
- Last Posted Date
- 2020-07-17
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT02805790
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of California, San Diego, California, United States
🇺🇸Children's Hospital of Pittsburg of UPMC, Pittsburgh, Pennsylvania, United States
Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction
- Conditions
- Heart Failure
- Interventions
- First Posted Date
- 2016-06-02
- Last Posted Date
- 2020-05-14
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 71
- Registration Number
- NCT02788747
- Locations
- 🇮🇹
A.O. Papa Giovanni XXIII Cardiologia 1, Torre 5, Bergamo, Italy
🇮🇹A.O. Spedali Civili di Brescia Cardiologia, Brescia, Italy
🇳🇱University Medical Centre Groningen, Groningen, Netherlands
A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Optic Neuropathy
- Conditions
- Leber's Hereditary Optic Neuropathy
- Interventions
- Drug: Vehicle topical ophthalmic solution
- First Posted Date
- 2016-02-26
- Last Posted Date
- 2021-11-30
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02693119
- Locations
- 🇺🇸
Doheny Eye Center, Pasadena, California, United States
A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)
- Conditions
- Fuchs' Corneal Endothelial Dystrophy (FCED)
- Interventions
- Drug: Part A PlaceboDrug: Part B Placebo
- First Posted Date
- 2016-01-12
- Last Posted Date
- 2021-09-17
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT02653391
- Locations
- 🇺🇸
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
🇺🇸Cincinnati Eye Institute, Edgewood, Kentucky, United States
A Phase 1 Study Investigating the Safety and Pharmacokinetics of Repeat-dose Intravenous Infusion of MTP-131 in Subjects With Impaired Renal Function
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT02436447
A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Bendaviaâ„¢ (MTP-131) in Patients With Heart Failure
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2015-10-15
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Registration Number
- NCT02388529
A Study Investigating the Safety, Tolerability, and Pharmacokinetics of MTP-131 in Subjects With Congestive Heart Failure
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2015-09-17
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT02388464
Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy
- Conditions
- Mitochondrial Myopathy
- Interventions
- First Posted Date
- 2015-02-20
- Last Posted Date
- 2019-12-27
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT02367014
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of California, San Diego, California, United States
🇺🇸Children's Hospital of Pittsburg of UPMC, Pittsburgh, Pennsylvania, United States
A Study of MTP-131 Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration
- Conditions
- Age-related Macular DegenerationDiabetic Macular Edema
- Interventions
- First Posted Date
- 2014-12-11
- Last Posted Date
- 2015-10-26
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02314299